6月4日 演題レポート
Abstract #3511
Analysis of KRAS / NRAS and BRAF Mutations in the Phase 3 PRIME Study of Panitumumab (pmab) plus FOLFOX versus FOLFOX as 1st-line Treatment (tx) for Metastatic Colorectal Cancer (mCRC).
Kelly S. Oliner, et al.
Abstract #3512
Heterogeneity of Acquired KRAS and EGFR Mutations in Colorectal Cancer Patients Treated with Anti-EGFR Monoclonal Antibodies
M. Pia Morelli, et al.
Abstract #3514
Analysis of Plasma Protein Biomarkers from the CORRECT Phase III Study of Regorafenib for Metastatic Colorectal Cancer.
Heinz-Josef Lenz, et al.
Abstract #3515
Maintenance Therapy with Bevacizumab with or without Erlotinib in Metastatic Colorectal Cancer (mCRC) According to KRAS: Results of the GERCOR DREAM Phase III Trial.
Christophe Tournigand, et al.
Abstract #3516
FOLFIRI plus Bevacizumab as Second-line Therapy in Patients with Metastatic Colorectal Cancer who Have Failed First-line Bevacizumab plus Oxaliplatin-based Therapy: The Randomized Phase III EAGLE Study.
Hiroshi Tamagawa, et al.
Abstract #3518
Non-inferiority of S-1 to UFT/LV as Adjuvant Chemotherapy for Stage III Colon Cancer: A Randomized Phase III Trial (ACTS-CC)
Yoshihiko Nakamoto, et al.
Abstract #3519
A Randomized Phase III Trial of S-1/Oxaliplatin (SOX) plus Bevacizumab versus 5-FU/l-LV/Oxaliplatin (mFOLFOX6) plus Bevacizumab in Patients with Metastatic Colorectal Cancer: The SOFT Study.
Daisuke Takahari, et al.
